Continue Reading
More from the Truli Journal
Ozempic changed the conversation. Suddenly everyone is talking about GLP-1 — as a drug, as a pathway, as a category. But the term is being used for two very different things, and the confusion is real. Here is a clear-eyed breakdown of what each approach actually does.
GLP-1 — glucagon-like peptide-1 — is a hormone your gut produces naturally after eating. It signals to your pancreas to release insulin, tells your brain you're full, slows gastric emptying, and reduces glucagon secretion. In short, it's one of the central mechanisms your body uses to regulate satiety and metabolic response to food.
In people with obesity or type 2 diabetes, this system is often impaired. The GLP-1 signal is weaker, the satiety response is blunted, and the feedback loop that should stop eating doesn't fire as strongly. This is the problem that GLP-1 drugs were developed to address — and the biological pathway that GLP-1 supplements attempt to support.
Both approaches engage the GLP-1 system. But how they do it, and with what level of force and risk, is entirely different.
GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) are synthetic molecules that directly activate GLP-1 receptors, bypassing the body's own hormone production. They do this at pharmacological doses — far exceeding anything the gut naturally produces — and they resist enzymatic degradation, so the signal persists for days to weeks depending on the formulation.
The result is powerful: dramatically reduced appetite, delayed gastric emptying, improved glycemic control. Clinical trials show average weight loss of 15–22% of body weight over 68 weeks — effects that are genuinely significant from a medical standpoint.
But because they operate at supraphysiological levels through direct receptor activation, they also carry a side effect profile reflective of that intensity: nausea, vomiting, diarrhea, constipation, and in some cases pancreatitis or thyroid concerns requiring ongoing medical monitoring. They also require injection (oral formulations exist but are less established), require a prescription, and typically cost $900–$1,400 per month without insurance.
GLP-1 supplements don't contain GLP-1. They don't mimic GLP-1 receptors directly. What they do — when well-formulated — is support the conditions under which your body's own GLP-1 pathway functions better.
This is a fundamentally different mechanism. Rather than overriding the system at pharmacological intensity, it works with the system — through ingredients that influence the upstream and downstream pathways that GLP-1 regulation depends on.
Berberine is one of the most-studied plant compounds in metabolic health research, with over 3,000 studies indexed in PubMed. Its primary mechanism is activation of AMPK — adenosine monophosphate-activated protein kinase — sometimes called the body's metabolic master switch. AMPK activation improves glucose uptake, reduces glucose production in the liver, and enhances insulin sensitivity.
Berberine also has direct GLP-1-adjacent effects: research shows it increases GLP-1 secretion from intestinal L-cells, increases GLP-1 receptor expression in key tissues, and inhibits DPP-4 — the enzyme that rapidly degrades endogenous GLP-1, usually within minutes of release. This means more of your body's own GLP-1 remains active for longer.
A meta-analysis comparing berberine to metformin (a first-line diabetes medication) found comparable HbA1c reduction over 12 weeks. This is not a trivial finding — it puts berberine in meaningful company while its side effect profile is dramatically gentler.
Chromium picolinate addresses a different but equally important layer: glucose variability. Blood glucose fluctuations — the spikes and crashes from refined carbohydrates — are one of the most reliable drivers of food cravings, because the brain interprets a glucose crash as a threat requiring immediate caloric input.
Chromium enhances insulin receptor sensitivity and improves the insulin response curve, leading to more stable post-meal glucose levels. The clinical evidence is consistent across multiple RCTs: chromium supplementation reduces carbohydrate cravings, reduces binge eating frequency, and improves overall satiety in populations with glucose dysregulation.
In the context of GLP-1 support, chromium's role is to reduce the glucose-driven signals that compete with — and can override — the satiety signals that berberine and L-theanine are working to amplify.
We want to be direct here, because the GLP-1 supplement category has some credibility problems — driven largely by brands making inflated claims and using the term "GLP-1" as marketing shorthand for dramatic weight loss results they can't deliver.
A GLP-1 supplement will not produce 15–20% body weight loss. That is a drug effect achieved through pharmacological receptor agonism at doses that require medical management. Anyone claiming a supplement can replicate that is misleading you.
What a well-formulated GLP-1 support supplement can do is meaningful in its own right:
Not a drug. Better than most supplements.
Berberine, L-Theanine, and Chromium Picolinate — clinical doses, no fillers, no inflated claims. Built for people who want genuine metabolic and behavioral support.
View the Full Formula →GLP-1 prescription drugs are appropriate for people with clinical obesity (BMI 30+), type 2 diabetes, or significant metabolic disease — when managed by a healthcare provider who can monitor for side effects and assess cardiovascular risk factors. If you're in that category, this is a legitimate medical conversation to have with your doctor. The evidence is real and the outcomes for appropriate patients are clinically meaningful.
GLP-1 support supplements — when properly formulated — are appropriate for a much broader population: people managing food noise and stress-driven eating, people on a GLP-1 medication looking for complementary support between doses, people who want to support their metabolic health without entering a prescription program, or people who've completed a GLP-1 drug course and are focused on maintenance.
They are not competing products in any meaningful sense. They address the GLP-1 system at entirely different points of intervention and at entirely different scales of effect.
We built Truli GLP-1 because we believe there is a real, underserved need for honest metabolic support that doesn't overpromise. The GLP-1 supplement category has been damaged by brands attaching themselves to Ozempic's halo while offering little more than green tea extract and marketing copy.
Our formula uses three ingredients at clinical doses, each with independent research supporting the specific mechanisms we're targeting. We don't claim to be a drug alternative. We claim to be a well-designed, evidence-informed supplement that does what it says it does.
If you're on a GLP-1 medication, we'd encourage you to talk to your provider before adding any supplement. If you're not, we'd encourage you to read the research on our three ingredients and form your own view. We're confident it holds up.
GLP-1 drugs are among the most effective medical interventions for obesity ever developed. They are also expensive, require prescriptions, carry real side effects, and are designed for clinical use in specific patient populations.
GLP-1 supplements — the honest ones — work through entirely different mechanisms to support the same biological system at a physiological rather than pharmacological level. The effect size is smaller, but the accessibility, safety profile, and cost profile are entirely different.
The question isn't which is "better" in the abstract. It's which is appropriate for your situation, your goals, and your current health status. And increasingly, for many people, the answer to that question involves both — a prescription program for acute intervention, and a supplement stack for long-term support.
Either way: demand evidence. Demand honesty about mechanisms and realistic effects. And be appropriately skeptical of anything that claims a supplement can do what a drug does.
